|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C22H20Cl2N4O4 |
|||
| Molecular Weight | 475.32 | CAS No. | 1360705-96-9 | |
| Solubility (25°C)* | In vitro | DMSO | 15 mg/mL (31.55 mM) | |
| Ethanol | 4 mg/mL (8.41 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | ML-210 (CID 49766530) is a selective covalent inhibitor of cellular glutathione peroxidase 4 (GPX4) with EC50 of 0.04 μM and induces ferroptosis. ML-210 can selectively kill cells induced to express mutant RAS. ML-210 exhibits anti-cancer activity. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro | ML-210 has IC50s of 71 nM, 272 nM and 107nM for BJeLR (HRASV12), BJeH-LT (without HRASV12) and DRD cell lines, respectively[2].[1] |
Protocol (from reference)
References
|
Selleck's ML 210 has been cited by 10 publications
| Coculture with macrophages alters ferroptosis susceptibility of triple-negative cancer cells [ Cell Death Discov, 2024, 10(1):108] | PubMed: 38429255 |
| Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo [ Sci Adv, 2024, 10(7):eadk1835] | PubMed: 38354236 |
| Accumulated cholesterol protects tumours from elevated lipid peroxidation in the microenvironment [ Redox Biol, 2023, 62:102678] | PubMed: 36940607 |
| Accumulated cholesterol protects tumours from elevated lipid peroxidation in the microenvironment [ Redox Biology, 2023, Volume 62] | PubMed: None |
| Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer [ Cell Death Dis, 2023, 14(8):532] | PubMed: 37596261 |
| Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients [ Bioengineered, 2022, 13(2):2498-2512] | PubMed: 35067161 |
| ATF6α promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis [ Prostate, 2022, 10.1002/pros.24308] | PubMed: 35089606 |
| Computational analysis of cholangiocarcinoma phosphoproteomes identifies patient-specific drug targets [ Cancer Res, 2021, canres.0955.2021] | PubMed: 34551960 |
| Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers [ Nat Chem Biol, 2020, 10.1038/s41589-020-0613-y] | PubMed: 32778843 |
| Cathepsin B is a mediator of organelle-specific initiation of ferroptosis [ Biochem Biophys Res Commun, 2020, 533(4):1464-1469] | PubMed: 33268027 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.